Company: IONQ
Filing Date: 2025-09-18
Form Type: 8-K/A
Source: 0001193125-25-206731
Chunk: 2

Company: IonQ, Inc.
Filing Date: 2025-09-18
Form: 8-K/A
Chunk 2
---
 Item 7.01 of this Form 8-K,including Exhibits 99.1 and 99.2, hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

| Item 8.01 | Other Events. |

On September 16, 2025, the Company completed its previously announced transaction (the “ Oxford Ionics Transaction”) to acquire all of the issued and outstanding shares of Oxford Ionics Limited, a private limited company incorporated in England and Wales (“ Oxford Ionics”), pursuant to the terms of the Share Purchase Agreement, dated June 7, 2025 (the “ Agreement”), among the Company, Oxford Ionics, the Sellers (as defined in the Agreement), and Oxford Science Enterprises plc, solely in its capacity as the representative of the Sellers. The aggregate consideration delivered at the closing of the Oxford Ionics Transaction consisted of 25,372,150 shares of the Company’s common stock (the “ Stock Consideration”) and $10,000,000 in cash. In connection with the closing of the Oxford Ionics Transaction and in connection with the issuance of the Stock Consideration, the Company and Oxford Science Enterprises plc, solely in its capacity as the representative of the Sellers (the “ Securityholders”), entered into a Registration Rights Agreement, dated September 16, 2025 (the “ Registration Rights Agreement”), pursuant to which the Securityholders will have certain registration rights relating to the Stock Consideration. The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such Registration Rights Agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-Kand is incorporated by reference herein.

#### In addition, on September 16, 2025, the Company entered into a definitive agreement to acquire Vector Atomic, Inc. in anall-stocktransaction (the “Vector Atomic Transaction”) for 6,294,058 shares of the Company’s common stock, subject to the terms and conditions of the definitive agreement and customary purchase price adjustments. The Vector Atomic Transaction is expected to close in the fourth quarter of 2025, subject to